United Therapeutics Corp

UTHR:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:50 AM EST
160.35quote price arrow down-4.50 (-2.73%)
Volume
19,043
52 week range
75.58 - 176.31

...

Loading . . .

KEY STATS

  • Open163.81
  • Day High163.81
  • Day Low158.74
  • Prev Close164.85
  • 52 Week High176.31
  • 52 Week High Date01/19/21
  • 52 Week Low75.58
  • 52 Week Low Date03/18/20
  • Market Cap7,125.73M
  • Shares Out44.44M
  • 10 Day Average Volume0.31M
  • Dividend-
  • Dividend Yield-
  • Beta0.42
  • 1 Year % Change78.4

RATIOS/PROFITABILITY

  • EPS (TTM)10.57
  • P/E (TTM)15.16
  • Fwd P/E (NTM)12.99
  • EBITDA (MRQ)641.10M
  • ROE (MRQ)15.62%
  • Revenue (MRQ)1,409.50M
  • Gross Margin (MRQ)92.76%
  • Net Margin (MRQ)33.25%
  • Debt To Equity (MRQ)24.37%

EVENTS

  • Earnings Date02/24/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest United Therapeutics Corp News

There is no recent news for this security.

Latest UTHR News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and...
Martine Rothblatt Ph.D. J.D.
Chairman
Christopher Patusky J.D.
Vice Chairman
Michael Benkowitz
President
James Edgemond
Chief Financial Officer
Paul Mahon J.D.
Executive Vice President
Address
1040 SPRING ST
Silver Spring, MD
20910
United States